

Gene Therapy

Part I: Technologies & Markets

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced and held academic positions in several countries including Switzerland, Germany, Canada and USA. After his retirement from neurosurgery, he is working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 172 articles out of a total of 1200 articles by 450 authors. These articles are updated on a yearly basis. Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2020) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). He is currently writing the "Handbook of Alzheimer Disease" to be published by Springer in 2022.

ABOUT THIS REPORT

Prof. Jain wrote the first commercial report on Gene Therapy in 1995, which was published by PJB Publication, London. This was followed by reports on Gene Therapy Vectors and Cancer Gene Therapy (1996). A report on Gene Therapy of Neurological Disorders was published by Decision Resources in 1997. In 1998, Prof. Jain wrote a Textbook of Gene Therapy, which was the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and continued to be updated online at Wiley's web site until 2003. In 2004, when the copyright reverted to Prof. Jain, it became part II of the Gene Therapy report. This report supersedes and updates all the previous books as well as reports.

November 2021
Copyright ©2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold, or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	21
1. Introduction	23
Definitions	23
Historical evolution of gene therapy	23
Relation of gene therapy to other biotechnologies.....	25
Molecular biological basics for gene therapy	26
Genome.....	26
DNA	27
RNA	27
<i>Transcriptome</i>	<i>28</i>
<i>RNA splicing</i>	<i>28</i>
Genes.....	29
<i>Silent gene mutations.....</i>	<i>29</i>
Gene regulation	30
Gene expression	30
ENCODE	31
Chromosomes	32
Telomeres.....	33
Mitochondria	33
Proteins	34
2. Gene Therapy Technologies	35
Classification of gene therapy techniques.....	35
Ex vivo and in vivo gene therapy	36
Ex vivo gene therapy.....	37
In vivo gene therapy	37
Physical methods of gene transfer.....	37
Electroporation	38
Applications of electroporation.....	38
<i>Clinical applications of electroporation</i>	<i>39</i>
<i>Advantages of electroporation</i>	<i>40</i>
<i>Limitations of electroporation</i>	<i>40</i>
Hydrodynamic	40
Microinjection	41
Particle bombardment	41
Ultrasound-mediated transfection	43
Molecular vibration.....	44
Application of pulsed magnetic field and superparamagnetic nanoparticles	44
Gene transfection using laser irradiation	44
Photochemical transfection.....	45
Chemical methods of gene transfer	45
Vectors for gene therapy	45
Basic considerations	45
Use of genes as pharmaceuticals	46
The ideal vector for gene therapy.....	46
Viral vectors.....	47
<i>Adenovirus vectors.....</i>	<i>47</i>
<i>Adeno-associated virus vectors.....</i>	<i>49</i>
<i>Alphavirus vectors.....</i>	<i>52</i>
<i>Baculovirus vectors</i>	<i>53</i>
<i>Foamy virus vectors.....</i>	<i>53</i>
<i>Herpes simplex virus vectors.....</i>	<i>54</i>
<i>Lentiviral vectors</i>	<i>56</i>
<i>Multicistronic retroviral vectors</i>	<i>57</i>
<i>Retroviral vectors.....</i>	<i>57</i>
<i>Oncogenic potential of retroviral vectors</i>	<i>59</i>
<i>Quantification of viral vectors</i>	<i>59</i>
<i>Future of viral vectors</i>	<i>60</i>
<i>Companies using viral vectors</i>	<i>60</i>
Nonviral vectors for gene therapy	61
<i>Anionic lipid-DNA complexes</i>	<i>62</i>
<i>Cationic lipid-DNA complexes</i>	<i>63</i>
<i>Effects of shape of DNA molecules on delivery with nonviral vectors.....</i>	<i>63</i>
<i>Electrostatic modifications of surface to improve gene delivery</i>	<i>63</i>
<i>Liposomes for gene therapy</i>	<i>63</i>
<i>Liposome-nucleic acid complexes.....</i>	<i>65</i>

<i>Liposome-HVJ complex</i>	65
<i>Transposons DNA vectors</i>	66
<i>Polycation-DNA complexes (polyplexes)</i>	67
<i>Plasmid DNA vs minicircle DNA</i>	68
<i>Polymer vectors for gene therapy</i>	68
<i>Synthetic biology and DNA vectors</i>	69
<i>Synthetic peptide complexes</i>	69
<i>Future of nonviral vs viral vectors</i>	70
Nanobiotechnology for gene therapy	70
<i>Antisense nanoparticles</i>	70
<i>Dendrimers</i>	71
<i>Cochleates</i>	71
<i>Calcium phosphate nanoparticles as nonviral vectors</i>	71
<i>DNA nanoparticles as nonviral vectors</i>	71
<i>Gelatin nanoparticles for gene delivery</i>	72
<i>Lipid nanoparticles for nucleic acid delivery</i>	72
<i>Nanoparticles as nonviral vectors for gene therapy</i>	72
<i>Nanoparticles with virus-like function as gene therapy vectors</i>	73
<i>Nanobiotistics for nucleic acid delivery</i>	73
<i>Nonionic polymeric micelles for oral gene delivery</i>	74
<i>Silica nanoparticles as a nonviral vector for gene delivery</i>	74
<i>Virus-like particles as nonviral vector</i>	74
Receptor-mediated endocytosis	74
Artificial viral vectors.....	76
Directed evolution of AAV to create efficient gene delivery vectors	76
Bacterial ghosts as DNA delivery systems	76
Bacteria plus nanoparticles for gene delivery into cells.....	77
Chromosome-based vectors for gene therapy	77
<i>Mammalian artificial chromosomes (MACs)</i>	77
<i>Human artificial chromosomes (HACs)</i>	78
<i>ΦC31 integrase system</i>	79
Companies using nonviral vectors	79
Concluding remarks about vectors	80
Gene repair and replacement	81
Gene repair by single-stranded oligonucleotides.....	81
History and current status of chimeraplasty	81
Genome editing	82
Gene editing by zinc finger nucleases	82
Gene editing by using short synthetic oligonucleotides.....	83
Genome engineering by using TALENs	84
Genome editing by homologous recombination	84
<i>GeneRide technology for genome editing</i>	84
Gene editing by homing endonucleases	85
<i>ARCUS genome editing technology</i>	85
Genome editing by using CRISPR system.....	86
<i>A method for generating genome-wide gRNA libraries for CRISPR</i>	87
<i>CRISPR-genome organization system</i>	87
<i>CRISPR vs other gene editing tools</i>	88
<i>CRISPR-FRT</i>	88
<i>CRISPR for studying human embryogenesis</i>	89
<i>CRISPR system for creating animal models of human diseases</i>	89
<i>CRISPR/Cas9 technology for drug discovery</i>	89
<i>CRISPR/Cas9-mediated epigenetic editing system</i>	90
<i>Engineered miniature CRISPR-Cas system</i>	90
<i>Expanding the range of Cas9s</i>	91
<i>Inducible CRISPR/Cas9 for multiple gene targeting</i>	91
<i>Lipid nanoparticles for delivery of CRISPR-Cas9 for genome-editing</i>	91
<i>Nanocapsules for delivery of CRISPR-Cas9 for genome editing</i>	91
<i>Nano-CRISPR</i>	92
<i>Photoactivatable CRISPR-Cas9</i>	92
<i>Protein delivery and genome editing</i>	92
<i>RNA editing with CRISPR-Cas9</i>	93
Potential clinical applications of CRISPR systems.....	93
<i>Autosomal dominant retinitis pigmentosa</i>	94
<i>Clinical trial of CRISPR in human cancer</i>	94
<i>CRISPR for glioblastoma</i>	94
<i>Correction of a gene mutation in the human embryo</i>	94
<i>Glaucoma</i>	95
<i>PERV blockage by CRISPR to facilitate xenotransplantation</i>	95
<i>RNA editing with CRISPR</i>	96
<i>Use of CRISPR for β-hemoglobinopathies</i>	96

<i>Use of CRISPR to restore hereditary hearing loss</i>	97
<i>Complications and limitations of CRISPR/Cas9 technology</i>	98
<i>Companies developing CRISPR technology</i>	99
Clinical studies of gene editing	100
Targeted genome editing by artificial nucleases	101
Ex vivo gene editing	101
DNA medicines based on gene editing	101
Comparison of gene editing with techniques for suppression of gene mutations	102
Future of gene editing	102
Base editing of the genome	103
Base editing by protein engineering.....	103
Adenine base editors for genomic DNA	103
Messenger RNA gene therapy	104
Spliceosome mediated RNA trans-splicing	104
Cell-mediated gene therapy	104
Fibroblasts	105
Skeletal muscle cells	106
Vascular smooth muscle cells	106
Keratinocytes	106
Hepatocytes	107
Lymphocytes.....	107
<i>Regulating protein delivery by genetically encoded lymphocytes</i>	107
Implantation of microencapsulated genetically modified cells	107
Stem cell gene therapy.....	108
<i>Combination of gene therapy with therapeutic cloning</i>	109
<i>Expansion of transduced HSCs in vivo</i>	109
<i>Gene delivery to stem cells by artificial chromosome expression</i>	109
<i>Improving delivery of genes to stem cells</i>	109
<i>In utero gene therapy using stem cells</i>	110
<i>Lentiviral vectors for gene transfer to marrow stem cells</i>	110
<i>Linker based sperm-mediated gene transfer technology</i>	110
<i>Mesenchymal stem cells for gene therapy</i>	110
<i>Microporation for transfection of MSCs</i>	111
<i>Preventing immune rejection of transplanted stem cells</i>	111
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	111
<i>Transdermal gene therapy for drug addiction</i>	111
<i>The future of hematopoietic stem cell gene therapy</i>	112
Chimeric antigen receptor T cells in relation to gene therapy	112
Basics of CAR-T cell.....	112
Basis of anticancer effect of CAR-T cells.....	112
<i>Smart T-cells</i>	113
CAR-T cell manufacture	113
Companies developing CAR-T cell therapy	113
CAR NK cells derived from human iPSCs	116
Genome editing of CAR-T cells.....	116
Safety and efficacy of CAR-T cell therapy	117
<i>Cytokine release syndrome</i>	117
<i>Precautions for CAR-T cell therapy</i>	118
Role of genetically modified bacteria in gene therapy	119
Routes of administration for gene therapy	119
Direct injection of naked DNA	120
Intramuscular injection	120
Intravenous DNA injection	120
Intraarterial delivery	121
Companies with gene delivery devices/technologies	121
Targeted gene therapy	122
Targeted integration.....	122
Bacteriophage integrase system for site-specific gene delivery	123
Controlled-release delivery of DNA	123
Controlled gene therapy	124
Controlled delivery of genetic material.....	124
Controlled induction of gene expression	124
Drug-inducible systems for control of gene expression.....	125
Timed activation of gene therapy by a circuit based on signaling network	125
Small molecules for post-transcriptional regulation of gene expression	125
Light Activated Gene Therapy.....	126
Spatial control of gene expression via local hyperthermia.....	126
Companies with regulated /targeted gene therapy	126
Gene marking	127
Germline gene therapy	127
Potential applications of human germline genome modification	128

Pros and cons of human germline genome modification	128
Role of gene transfer in antibody therapy.....	130
Genetically engineered vaccines	130
DNA vaccines	130
<i>DNA inoculation technology.....</i>	<i>131</i>
<i>Methods for enhancing the potency of DNA vaccines</i>	<i>131</i>
<i>Advantages of DNA vaccines</i>	<i>131</i>
Vaccine vectors	132
Challenges and limitations of genetically engineered vaccines.....	133
RNA vaccines.....	133
<i>Nonviral delivery of self-amplifying RNA vaccine</i>	<i>133</i>
Vaccines based on reverse genetics.....	134
Technologies for gene suppression.....	134
Antisense oligonucleotides	134
Transcription factor decoys	135
Aptamers.....	135
Ribozymes	136
Peptide nucleic acid.....	136
<i>Intracellular delivery of PNAs.....</i>	<i>136</i>
Locked nucleic acid	137
<i>Zorro-LNA.....</i>	<i>137</i>
Gene silencing	137
Post-transcriptional gene silencing	137
Definitions and terminology of RNAi	138
RNAi mechanisms	138
Inhibition of gene expression by antigen RNA	139
RNAi gene therapy	139
microRNA gene therapy	139
Viral vectors for RNAi and miRNA gene therapy	140
Application of molecular diagnostic methods in gene therapy	141
Use of PCR to study biodistribution of gene therapy vector.....	141
PCR for verification of the transcription of DNA	141
In situ PCR for direct quantification of gene transfer into cells	142
Detection of retroviruses by reverse transcriptase (RT)-PCR.....	142
Confirmation of viral vector integration.....	142
Monitoring of gene expression	142
<i>Monitoring of gene expression by green fluorescent protein.....</i>	<i>143</i>
<i>Monitoring in vivo gene expression by molecular imaging.....</i>	<i>143</i>
<i>Advantages of gene therapy compared with protein therapy.....</i>	<i>143</i>
Gene therapy manufacture	144
Formulation, transport, and storage of materials for gene therapy	144
 3. Clinical Applications of Gene Therapy	 145
Introduction	145
Aging-related disorders	145
Telomerase gene therapy in aging	145
Combination gene therapy for treatment of multiple age-related diseases.....	145
Bone and joint disorders.....	146
Bone fractures.....	146
Gene therapy for intervertebral disc degeneration.....	147
Spinal fusion	147
Osteogenesis imperfecta	148
Rheumatoid arthritis.....	148
<i>Local or systemic treatment</i>	<i>149</i>
<i>In vivo or ex vivo gene therapy of RA.....</i>	<i>149</i>
<i>Clinical trials of gene therapy for rheumatoid arthritis.....</i>	<i>150</i>
Gene therapy for osteoarthritis.....	151
<i>Gene therapy strategies for osteoarthritis</i>	<i>151</i>
<i>Clinical trials of gene therapy for osteoarthritis.....</i>	<i>152</i>
Sports injuries.....	152
<i>Repair of articular cartilage defects</i>	<i>153</i>
Regeneration and replacement of bone by gene therapy	153
Bacterial infections	154
Antisense approach to bacterial infections	154
Dentistry.....	155
Tissue engineering in dental implant defects	155
Endocrine and metabolic disorders	155
Introduction	155
Gene therapy of obesity.....	156
<i>AAV vector-mediated delivery of GDNF for obesity</i>	<i>156</i>
<i>Oligopeptide for targeted nonviral gene delivery to adipocytes.....</i>	<i>156</i>

<i>Viral vector-mediated leptin gene therapy</i>	157
Diabetes mellitus	157
Methods of gene therapy of diabetes mellitus	158
<i>Viral vector-mediated gene transfer in diabetes</i>	158
<i>Endogenous reprogramming of α cells into β cells</i>	159
<i>Gene delivery with ultrasonic microbubble destruction technology</i>	159
<i>Genetically engineered cells for diabetes mellitus</i>	160
<i>Genetically altered liver cells</i>	160
<i>Genetically modified stem cells</i>	160
<i>Genetically engineered dendritic cells</i>	161
<i>Glucokinase and insulin co-expression</i>	161
<i>Leptin gene therapy</i>	161
<i>Concluding remarks about cell and gene therapy of diabetes</i>	161
Gene therapy of growth-hormone deficiency	162
Gastrointestinal disorders	163
Introduction	163
Methods of gene transfer to the gastrointestinal tract	163
<i>Direct delivery of genes</i>	163
<i>Naked plasmid DNA into the submucosa</i>	164
<i>Viral vectors</i>	164
<i>Receptor-mediated endocytosis</i>	164
Indications for gastrointestinal gene therapy	164
<i>Gene therapy for inflammatory disorders of the bowel</i>	165
Gene transfer to the salivary glands	165
<i>Potential clinical applications of salivary gene therapy</i>	166
Hematology	166
Hemophilias	167
<i>Gene therapy of hemophilia</i>	167
<i>Hemophilia A</i>	168
<i>Hemophilia B</i>	169
<i>Concluding remarks about gene therapy of hemophilias</i>	171
Hemoglobinopathies	172
<i>Gene therapy for β-thalassemia</i>	172
<i>Gene therapy for sickle cell disease</i>	174
<i>HSC-targeted gene therapy for SCD</i>	174
<i>Gene therapy and RNAi for SCD based on stem cells</i>	174
<i>Gene editing in sickle cell disease</i>	175
<i>Gene editing using ZFN as treatment for both SCD and β-thalassemia</i>	175
<i>Gene editing using CRISPR-Cas9 for both SCD and β-thalassemia</i>	176
<i>Gene therapy of Fanconi's anemia</i>	176
Acquired hematopoietic disorders	177
<i>Chronic acquired anemias</i>	177
<i>Neutropenia</i>	177
<i>Thrombocytopenia</i>	178
Concluding remarks about gene therapy of hemoglobinopathies	179
Companies involved in gene therapy of hematological disorders	179
In utero/fetal gene therapy	179
Fetal gene transfer techniques	180
Animal models of fetal gene therapy	181
Potential applications of fetal gene therapy	181
<i>Fetal gene therapy for cystic fibrosis</i>	181
<i>Fetal intestinal gene therapy</i>	182
<i>Gene therapy for fetal growth restriction</i>	182
Hearing disorders	182
Potential of gene therapy	183
Vectors for gene therapy of hearing disorders	183
Auditory hair cell replacement and hearing improvement by gene therapy	184
Kidney diseases	184
End-stage renal disease	184
Methods of gene delivery to the kidney	185
<i>Bone marrow stem cells for renal disease</i>	185
<i>Gene transfer into kidney by viral vectors</i>	186
<i>Gene transfer into the glomerulus by HVJ-liposome</i>	186
<i>Gene transfer to tubules with cationic polymer polyethylenimine</i>	186
<i>Liposome-mediated gene transfer into the tubules</i>	186
<i>Mesangial cell therapy</i>	187
<i>Non-viral gene transfer to the kidneys</i>	187
Gene therapy in animal experimental models of renal disease	187
Genetic manipulations of the embryonic kidney	188
Antisense intervention in glomerulonephritis	188
Gene therapy for renal fibrosis	188

Use of genetically engineered cells for uremia due to renal failure	189
Concluding remarks	189
Liver disorders.....	189
Techniques of gene delivery to liver	190
<i>Direct injection of DNA into liver</i>	191
<i>Local gene delivery by isolated organ perfusion</i>	191
<i>Liposome-mediated direct gene transfer</i>	191
<i>Retroviral vector for gene transfer to liver</i>	191
<i>Adenoviral vectors for gene transfer to liver</i>	191
<i>Receptor-mediated approach</i>	192
Cell therapy for liver disorders.....	192
<i>Transplantation of genetically modified hepatocytes</i>	192
<i>Genetically modified hematopoietic stem cells</i>	193
<i>Gene therapy by ex vivo transduced liver progenitor cells</i>	193
Gene therapy of genetic diseases affecting the liver	193
<i>Crigler-Najjar syndrome</i>	193
<i>Hereditary tyrosinemia type I (HT1)</i>	194
<i>Hereditary tyrosinemia type 3</i>	194
<i>Wilson's disease</i>	195
Gene therapy of acquired diseases affecting the liver	195
<i>Cirrhosis of liver</i>	195
Ophthalmic disorders.....	195
Introduction to gene therapy of ophthalmic disorders	195
Methods of gene therapy for ophthalmic disorders	196
<i>Delivery of gene therapy by intravitreal injection</i>	197
<i>DNA nanoparticles for nonviral gene transfer to the eye</i>	198
<i>Optogenetic gene therapy for blindness due to retinal degeneration</i>	198
Age-related macular degeneration	199
Inherited disorders of optic nerve affecting vision	200
<i>Leber hereditary optic neuropathy</i>	201
<i>Gene therapy for LHON</i>	201
Inherited retinal degenerations.....	202
<i>Choroideremia</i>	203
<i>Leber congenital amaurosis</i>	203
<i>Monogenic macular degeneration due to mutations in the BEST1 gene</i>	205
<i>Retinitis pigmentosa</i>	205
<i>Stargardt disease</i>	207
Other inherited disorders affecting vision	207
<i>Color blindness</i>	207
<i>Usher syndrome</i>	208
<i>X-linked retinoschisis</i>	209
Diabetic retinopathy	209
Future of gene therapy of inherited retinal degenerations	210
<i>Combining cell and gene therapies for retinal disorders</i>	210
Prevention of complications associated with eye surgery.....	211
<i>Prevention of proliferative retinopathy by gene therapy</i>	211
<i>Posterior capsule opacification after cataract surgery</i>	211
Autoimmune uveitis	211
Retinal ischemic injury.....	211
Corneal disorders.....	212
Glaucoma	212
Corneal scarring	213
Companies developing gene therapy for eye disorders.....	213
Organ transplantation.....	213
Introduction	213
DNA vaccines for transplantation	214
Gene therapy for prolonging allograft survival	214
<i>Genetically modified Tregs expressing CAR for preventing GVHD</i>	214
Gene therapy in lung transplantation.....	215
Role of gene therapy in liver transplantation	215
Gene therapy in kidney transplantation.....	215
Veto cells and transplant tolerance.....	216
Pulmonary disorders.....	216
Techniques of gene delivery to the lungs	216
<i>Adenoviral vectors</i>	217
<i>Nonviral vectors</i>	218
<i>Aerosolization as an aid to gene transfer to lungs</i>	218
Cystic fibrosis	218
<i>Genetics and clinical features</i>	218
<i>Gene therapy for CF</i>	219
<i>CFTR gene transfer in CF</i>	219

Concluding remarks about gene therapy of CF	220
Miscellaneous pulmonary disorders	221
Gene therapy for pulmonary arterial hypertension.....	221
Gene therapy for bleomycin-induced pulmonary fibrosis	222
Gene therapy of emphysema due to α 1-antitrypsin deficiency	222
Gene therapy for asthma	222
Gene therapy for adult respiratory distress syndrome.....	223
Gene therapy for lung injury	223
Gene therapy for bronchopulmonary dysplasia.....	223
Concluding remarks about gene therapy of lungs.....	224
Companies involved in pulmonary gene therapy	224
Skin and soft tissue disorders.....	225
Gene transfer to the skin	225
Electroporation for transdermal delivery of plasmid DNA	225
Electroporation for transdermal delivery of DNA vaccines	225
Liposomes for transdermal gene delivery	226
Ultrasound and topical gene therapy	226
Gene therapy in skin disorders	226
Gene therapy of hair loss	226
Gene therapy for epidermolysis bullosa.....	227
Gene therapy for xeroderma pigmentosa	228
Gene therapy for lamellar ichthyosis.....	229
Gene transfer techniques for wound healing	229
Urogenital disorders	230
Gene therapy for urinary tract dysfunction	230
Gene therapy for erectile dysfunction	230
NOS gene transfer for erectile dysfunction	230
Clinical trial of hMaxi-K Gene transfer in erectile dysfunction	230
Gene therapy for erectile dysfunction due to nerve injury.....	231
Concluding remarks on gene therapy for erectile dysfunction.....	231
Gene therapy of miscellaneous disorders	231
Primary Sjögren's syndrome.....	231
Veterinary gene therapy	232
Gene therapy for mucopolysaccharidosis VII in dogs	232
Gene therapy to increase disease resistance.....	232
Gene therapy for infections	233
Gene therapy for chronic anemia	233
Gene therapy for endocrine disorders	233
Gene therapy for arthritis.....	234
Cancer gene therapy	234
Brain tumors in cats and dogs	234
Breast cancer in dogs	235
Canine hemangiosarcoma	235
Canine melanoma	236
Canine soft tissue sarcoma.....	236
Melanoma in horses	236
4. Gene Therapy of Genetic Disorders.....	237
Introduction	237
Primary immunodeficiency disorders.....	238
Severe combined immune deficiency	239
Gene therapy for SCID	239
Lentiviral gene therapy combined with low-dose busulfan for SCID-X1	242
Chronic granulomatous disease	242
Wiskott-Aldrich syndrome	243
Purine nucleoside phosphorylase deficiency	244
Major histocompatibility class II deficiency	244
Future prospects of gene therapy of inherited immunodeficiencies	244
Metabolic disorders.....	245
Alpha1-antitrypsin deficiency.....	245
AAV mediated gene therapy for α 1-antitrypsin deficiency.....	246
iPSCs for targeted gene correction of α 1-antitrypsin deficiency	247
Gene editing for AAT deficiency	248
Adrenoleukodystrophy	249
Canavan disease.....	250
Lesch-Nyhan syndrome	250
Lipoprotein lipase deficiency.....	251
Alipogene tiparvovec	251
Ornithine transcarbamylase deficiency.....	251
Gene therapy for OTCD.....	252
AAV-mediated gene editing for OTCD using CRISPR-Cas9	252

Phenylketonuria	253
Porphyrias	253
Tetrahydrobiopterin deficiency	254
Lysosomal storage disorders.	254
Batten disease	255
Fabry's disease	256
Farber's disease	257
Gaucher disease	257
<i>Animals models of Gaucher's disease</i>	257
<i>Gene therapy of Gaucher's disease</i>	258
Glycogen storage disorders	258
<i>Glycogen storage disease type I</i>	258
<i>Gene therapy of GSD1a</i>	259
Hunter syndrome	259
Krabbe's disease	260
Metachromatic leukodystrophy	260
Mucopolysaccharidosis type 1 (Hurler syndrome)	261
Niemann-Pick type A disease	262
Pompe disease	262
Sanfilippo A syndrome	263
Sly syndrome	264
Tay-Sachs disease/Sandhoff disease	264
Future of gene therapy of lysosomal storage disorders	265
Trinucleotide repeat disorders	265
Muscular dystrophies	265
Duchenne muscular dystrophy (DMD)	265
<i>Animal models for gene therapy of DMD</i>	266
<i>Antisense approaches to DMD</i>	266
<i>CRISPR/Cas9 gene editing for DMD</i>	267
<i>Exon-skipping for DMD</i>	267
<i>Galgt2 gene therapy</i>	268
<i>Liposome-mediated gene transfer</i>	269
<i>Microdystrophin gene therapy</i>	269
<i>Myoblast-based gene transfer in DMD</i>	269
<i>Plasmid-mediated gene therapy</i>	270
<i>Purinoreceptor P2RX7 ablation</i>	270
<i>Post-transcriptional modulation of gene expression in DMD</i>	270
<i>Repair/Editing of dystrophin gene</i>	270
<i>Routes of administration of gene therapy in DMD</i>	273
<i>Types of dystrophin constructs</i>	274
<i>Viral vectors for DMD</i>	274
<i>Conclusions and future of gene therapy of DMD</i>	275
Limb-girdle muscular dystrophy	276
Myotonic dystrophy	276
Spinal muscular atrophy	277
<i>Gene therapy strategies for SMA</i>	277
<i>Zolgensma® gene therapy for SMA</i>	277
<i>Antisense approaches for SMA</i>	278
<i>Nusinersen</i>	278
<i>Nusinersen vs Zolgensma® gene therapy for SMA</i>	279
X-linked myotubular myopathy (XLMTM)	279
Hereditary neuropathies	279
Charcot-Marie-Tooth disease	279
Hereditary axonal neuropathies of the peripheral nerves	280
Gene editing for hereditary transthyretin amyloidosis	280
Current therapies for ATTR amyloidosis	280
CRISPR-Cas9 gene editing for ATTR amyloidosis	281
Gene therapy of mitochondrial disorders	281
Techniques for mitochondrial replacement therapy	282
Status of mitochondrial replacement and transfer therapies	283
Barth syndrome	284
Companies involved in gene therapy of genetic disorders	284
5. Gene Therapy of Cancer	285
Strategies for cancer gene therapy	285
Direct gene delivery to the tumor	286
Injection into tumor	286
<i>Direct injection of adenoviral vectors</i>	286
<i>Direct injection of a plasmid DNA-liposome complex</i>	287
<i>A polymer approach to local gene therapy for cancer</i>	287
Electroporation for cancer gene therapy	287

Control of gene expression in tumor by local heat	288
Radiation-guided gene therapy of cancer	288
Radioprotective gene therapy of cancer	288
Nanoparticles to facilitate combination of hyperthermia and gene therapy.....	289
Immunogene therapy of cancer	289
Cell-based cancer gene therapy	290
Adoptive cell therapy.....	290
CAR-T cell therapy for cancer	291
<i>CAR-T cells for tumor targeting.....</i>	<i>291</i>
<i>CAR-T cells targeting both CD19 and CD22</i>	<i>291</i>
<i>Remote control of CAR-T cells for cancer immunotherapy</i>	<i>291</i>
<i>CAR-T cell therapy for leukemia.....</i>	<i>292</i>
<i>CAR-T cell therapy for multiple myeloma</i>	<i>293</i>
<i>CAR-T cell therapy for lymphoma.....</i>	<i>293</i>
<i>CAR-T cell therapy for solid tumors</i>	<i>294</i>
Cytokine gene therapy.....	295
Genetic modification of human hematopoietic stem cells.....	298
Cancer vaccines	298
Genetically modified cancer cell vaccines	298
<i>GVAX cancer vaccines</i>	<i>299</i>
<i>Genetically modified dendritic cells.....</i>	<i>299</i>
Nucleic acid-based cancer vaccines	300
<i>DNA cancer vaccines</i>	<i>300</i>
<i>RNA vaccines.....</i>	<i>300</i>
Viral vector-based cancer vaccines.....	300
<i>Intradermal delivery of cancer vaccines by Ad vectors</i>	<i>301</i>
Vaccines based on genetically engineered nonviral vectors.....	301
Future of cancer vaccines.....	301
Companies involved in nucleic acid-based cancer vaccines	302
Monoclonal antibody gene transfer for cancer	303
Transfer and expression of intracellular adhesion-1 molecules	303
Other gene therapy techniques for immunotherapy of cancer	303
Chemokines	303
CRISPR for immunogene therapy	304
Engineered viruses as anticancer immunotherapy vectors	305
Fas (Apo-1).....	305
Major Histocompatibility Complex (MHC) Class I	305
IGF (Insulin-Like Growth Factor).....	305
Cancer immunotherapies targeting multiple mechanisms.....	306
Inhibition of immunosuppressive function in cancer	306
Delivery of toxic genes to tumor cells for eradication	306
Gene-directed enzyme prodrug therapy	306
Combination of gene therapy with radiotherapy	307
Correction of genetic defects in cancer cells	307
Targeted gene therapy for cancer.....	308
Antiangiogenic therapy for cancer	308
Bacteria as novel anticancer gene vectors	309
Cancer-specific gene expression	309
Cancer-specific transcription.....	310
Delivery of retroviral particles hitchhiking on T cells	310
Electrogene and electrochemotherapy	310
Epidermal growth factor-mediated DNA delivery	310
Gene expression in hypoxic tumor cells	311
Genetically modified T cells for targeting tumors.....	311
Genetically engineered stem cells for targeting tumors	312
Hematopoietic stem cells for targeted cancer gene therapy	312
Immunolipoplex for delivery of p53 gene	313
Nanomagnets for targeted cell-based cancer gene therapy.....	313
Nanoparticles for targeted site-specific delivery of anticancer genes	314
Targeted cancer therapy using a dendrimer-based synthetic vector.....	314
Tumor-targeted gene therapy by receptor-mediated endocytosis	314
Virus-mediated oncolysis.....	315
Cytokine-induced killer cells for delivery of an oncolytic virus	315
Monitoring of viral-mediated oncolysis by PET	315
Oncolytic adenoviruses	316
Oncolytic HSV.....	317
Oncolytic measles viruses	317
Oncolytic vaccinia virus.....	318
Oncolytic vesicular stomatitis virus.....	318
Targeted cancer treatments based on oncolytic viruses.....	318
Concluding remarks on oncolytic gene therapy	319

Companies developing oncolytic viruses.....	319
Apoptotic approach to improve cancer gene therapy	320
Tumor suppressor gene therapy	321
P53 gene therapy.....	321
BRIT1 gene therapy	321
Nitric oxide-based cancer gene therapy.....	321
Anticancer effect of nitric oxide synthase	321
Gene therapy for radiosensitization of cancer	322
Gene therapy of cancer of selected organs	322
Gene therapy for bladder cancer.....	322
Gene therapy for glioblastoma.....	323
<i>Adenoviral vectors for treatment of brain tumors</i>	<i>324</i>
<i>Antiangiogenic gene therapy</i>	<i>324</i>
<i>Autophagy induced by conditionally replicating adenoviruses.....</i>	<i>325</i>
<i>Baculovirus vector for diphtheria toxin gene therapy</i>	<i>325</i>
<i>Cerepro® (sitimagene ceradenovec)</i>	<i>325</i>
<i>Gene therapy targeting hepatocyte growth factor.....</i>	<i>326</i>
<i>Genetically engineered MSCs for gene delivery to intracranial gliomas</i>	<i>326</i>
<i>Intravenous gene delivery with nanoparticles into brain tumors.....</i>	<i>326</i>
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	<i>327</i>
<i>Olig2 targeting to hinder growth of treatment-resistant glioblastomas</i>	<i>327</i>
<i>Oncolytic immunovirotherapy for pediatric high-grade gliomas</i>	<i>327</i>
<i>RNAi gene therapy of brain cancer</i>	<i>327</i>
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i>	<i>328</i>
<i>Viral oncolysis of glioblastoma multiforme.....</i>	<i>328</i>
Gene therapy for breast cancer.....	330
<i>Gene vaccine for breast cancer</i>	<i>330</i>
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	<i>331</i>
Gene Therapy for ovarian cancer	331
Gene therapy for malignant melanoma	332
<i>Immunogene therapy.....</i>	<i>333</i>
<i>Nonviral immunogene therapy for malignant melanoma.....</i>	<i>334</i>
<i>Oncogene targeted therapy.....</i>	<i>334</i>
<i>Targeted gene therapy for malignant melanoma</i>	<i>334</i>
Gene therapy of lung cancer.....	334
<i>Intravenous nanoparticle formulation for delivery of FUS1 gene.....</i>	<i>335</i>
<i>Aerosol gene delivery for lung cancer</i>	<i>335</i>
Gene therapy for cancer of prostate	335
<i>Experimental studies</i>	<i>335</i>
<i>Nanoparticle-based gene therapy for prostate cancer</i>	<i>336</i>
<i>Tumor suppressor gene therapy in prostate cancer</i>	<i>336</i>
<i>Vaccines for prostate cancer.....</i>	<i>336</i>
<i>Viral oncolysis for prostate cancer</i>	<i>337</i>
<i>Clinical trials of gene therapy for prostate cancer.....</i>	<i>337</i>
Gene therapy of head and neck cancer	337
<i>Adenoviral vector based P53 gene therapy.....</i>	<i>338</i>
<i>Gene therapy as adjunct to 5-FU for nasopharyngeal carcinoma</i>	<i>338</i>
Gene therapy of pancreatic tumors	338
<i>Pancreatic neuroendocrine tumors</i>	<i>338</i>
<i>Pancreatic ductal adenocarcinoma.....</i>	<i>339</i>
<i>Editing of altered genes</i>	<i>339</i>
<i>Targeted gene therapy</i>	<i>340</i>
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens.....</i>	<i>340</i>
<i>Targeted Expression of BikDD gene.....</i>	<i>340</i>
<i>Viral oncolysis in pancreatic cancer</i>	<i>341</i>
<i>Concluding remarks on gene therapy of pancreatic cancer</i>	<i>341</i>
Gene therapy of renal cancer.....	341
<i>Viral oncolytic therapy for renal cancer</i>	<i>341</i>
Gene therapy of hematological malignancies	341
<i>Genetically engineered T lymphocytes</i>	<i>341</i>
Cancer gene therapy companies	342

6. Gene Therapy of Neurological Disorders 345

Indications 345

Gene transfer techniques for the nervous system..... 346

Methods of gene transfer to the nervous system	346
Ideal vector for gene therapy of neurological disorders	346
Promoters of gene transfer.....	346
Lentivirus-mediated gene transfer to the CNS	347
AAV vector mediated gene therapy for neurogenetic disorders.....	347
Gene transfer to the CNS using recombinant SV40-derived vectors	348

Routes of delivery of genes to the nervous system.....	348
<i>Direct injection into CNS.....</i>	348
<i>Introduction of the genes into cerebral circulation.....</i>	349
<i>Introduction of genes into cerebrospinal fluid.....</i>	349
<i>Intravenous administration of vectors.....</i>	350
Delivery of gene therapy to the peripheral nervous system	350
Cell-mediated gene therapy of neurological disorders	350
<i>Neuronal cells.....</i>	350
<i>Neural stem cells and progenitor cells.....</i>	350
<i>Astrocytes.....</i>	351
<i>Cerebral endothelial cells</i>	351
<i>Implantation of genetically modified encapsulated cells into the brain.....</i>	351
Gene transfer for neuromodulation.....	352
Monitoring of CNS gene therapy	352
Gene therapy of neurodegenerative disorders	352
Gene therapy for Parkinson disease.....	352
Rationale	353
<i>Techniques of gene therapy for PD.....</i>	354
<i>Augmenting CNS glucocerebrosidase activity.....</i>	357
<i>Delivery of neurotrophic factors by gene therapy</i>	357
<i>Delivery of parkin gene.....</i>	358
<i>Gene editing in PD</i>	358
<i>Introduction of functional genes into the brain of patients with PD</i>	358
<i>Nanoparticle-based gene therapy for PD</i>	359
<i>Mitochondrial gene therapy for PD.....</i>	359
<i>RNAi approach to PD</i>	359
<i>Viral vector-based ubiquitination to prevent spread of α-synuclein</i>	360
<i>Prospects of gene therapy for PD</i>	360
<i>Concluding remarks about gene therapy of PD.....</i>	361
<i>Companies developing gene therapy for PD.....</i>	361
Gene therapy for Alzheimer disease	362
Rationale	362
<i>NGF gene therapy for AD</i>	362
<i>FGF2 gene transfer in AD</i>	363
Gene therapy for restoring brain cholesterol metabolism.....	363
<i>Nepriylsin gene therapy</i>	364
<i>Viral gene transfer of APPsa for rescuing synaptic failure in AD</i>	364
<i>Gene vaccination</i>	365
<i>Combination of gene therapy with other treatments for AD</i>	365
Gene therapy of Huntington disease.....	365
<i>Encapsulated genetically engineered cellular implants.....</i>	365
<i>Viral vector mediated administration of neurotrophic factors</i>	366
<i>RNAi gene therapy</i>	366
Gene therapy of amyotrophic lateral sclerosis.....	366
Rationale	366
<i>Technique of gene therapy of ALS.....</i>	366
<i>Other approaches to gene therapy of ALS</i>	368
Gene therapy of cerebrovascular diseases.....	368
Preclinical research in gene therapy for cerebrovascular disease	368
Animal models of stroke relevant to gene therapy	369
<i>Transgenic mice as models for stroke</i>	369
<i>Animal models for gene therapy of arteriovenous malformations.....</i>	369
Gene transfer to cerebral blood vessels	369
Gene therapy for vasospasm following subarachnoid hemorrhage	370
<i>NOS gene therapy for cerebral vasospasm</i>	371
Gene therapy for stroke.....	372
<i>Gene therapy for stroke using neurotrophic factors</i>	373
<i>Gene therapy of strokes with a genetic component</i>	373
<i>Gene therapy for intracranial aneurysms.....</i>	373
<i>RNAi-based gene silencing for neuroprotection in cerebral ischemia</i>	374
Concluding remarks about gene therapy for stroke.....	374
Gene therapy of injuries to the nervous system.....	374
Traumatic brain injury	374
Spinal cord injury.....	375
Peripheral nerve injuries	376
Gene therapy of epilepsy	376
Gene therapy for control of seizures	376
Gene therapy for neuroprotection in epilepsy	377
Gene therapy for genetic forms of epilepsy	378
Gene therapy for multiple sclerosis	378
Gene therapy for impairment of special senses	378

Gene therapy for hearing loss.....	379
Gene therapy for olfactory impairment	379
Gene therapy for relief of pain	380
Rationale of gene therapy for pain	380
Vectors for gene therapy of pain	380
Methods of gene delivery for pain	381
<i>Endogenous analgesic production for cranial neuralgias</i>	<i>381</i>
<i>Gene delivery by intrathecal route</i>	<i>382</i>
<i>Gene transfer for delivery of analgesics to the spinal nerve roots</i>	<i>382</i>
<i>Gene therapy of peripheral neuropathic pain</i>	<i>383</i>
<i>Gene transfer by injections into the brain substance.....</i>	<i>384</i>
Targets for gene therapy of pain	384
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	<i>384</i>
<i>Gene therapy for producing enkephalin to block pain signals</i>	<i>385</i>
<i>Targeting nuclear factor-κB</i>	<i>385</i>
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	<i>385</i>
Potential applications of gene therapy for management of pain.....	386
Concluding remarks on gene therapy for pain	386
Gene therapy for psychiatric disorders	387
Gene therapy for depression	387
Gene therapy for enhancing cognition after stress.....	388
Gene therapy against fear disorders	388
Companies involved in gene therapy of neurological disorders.....	389

7. Gene Therapy of Cardiovascular Disorders 391

Introduction	391
Techniques of gene transfer to the cardiovascular system	391
Direct plasmid injection into the myocardium	392
Catheter-based systems for vector delivery	392
Ultrasound microbubbles for cardiovascular gene delivery	393
Vectors for cardiovascular gene therapy	393
<i>AAV vectors for therapeutic delivery to the heart</i>	<i>393</i>
<i>Adenoviral vectors for cardiovascular diseases.....</i>	<i>394</i>
<i>Molecular cardiac surgery with recirculating delivery of AAV vectors</i>	<i>394</i>
<i>Plasmid DNA-based delivery in cardiovascular disorders.....</i>	<i>394</i>
Gene therapy for counteracting hypoxia in myocardial ischemia.....	394
Therapeutic angiogenesis vs vascular growth factor therapy.....	395
Gene painting for delivery of targeted gene therapy to the heart	395
Gene delivery to vascular endothelium	396
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles	396
Vascular stents for gene delivery	397
Gene therapy for genetic cardiovascular disorders	397
Catecholaminergic polymorphic ventricular tachycardia.....	397
Genetic disorders predisposing to atherosclerosis.....	398
Familial hypercholesterolemia.....	399
Apolipoprotein E deficiency.....	400
Hypertension.....	400
Genetic factors for myocardial infarction	401
Acquired cardiovascular diseases	402
Coronary artery disease with angina pectoris.....	402
<i>Ad5FGF-4.....</i>	<i>402</i>
Gene therapy for improving long-term CABG patency rates.....	403
Ischemic heart disease with myocardial infarction	403
<i>Gene therapy and angiogenesis in ischemic heart disease</i>	<i>403</i>
<i>Induction of angiogenesis in myocardium by HEXIM1 re-expression</i>	<i>404</i>
<i>Myocardial repair with IGF-1 therapy.....</i>	<i>405</i>
<i>Metalloproteinase-2 inhibitor gene therapy.....</i>	<i>405</i>
<i>miRNA gene therapy for ischemic heart disease</i>	<i>406</i>
Congestive heart failure.....	406
<i>Rationale of gene therapy in CHF</i>	<i>406</i>
<i>AAV-mediated gene transfer for CHF</i>	<i>406</i>
<i>AngioCell gene therapy for CHF</i>	<i>407</i>
<i>β-ARKct gene therapy.....</i>	<i>408</i>
<i>Elevating cardiac dATP by gene therapy to improve cardiac function.....</i>	<i>408</i>
<i>Elevating cardiac adenyl cyclase type 6 to improve cardiac function.....</i>	<i>409</i>
<i>Intracoronary adenovirus-mediated gene therapy for CHF.....</i>	<i>409</i>
<i>nNOS gene transfer in CHF.....</i>	<i>410</i>
Cardiomyopathies	410
Cardiac arrhythmias	410
<i>Gene transfer approaches for biological pacemakers.....</i>	<i>411</i>
<i>Genetically engineered biological pacemakers.....</i>	<i>412</i>

Gene therapy for ventricular arrhythmia	412
Gene therapy and heart transplantation	412
Hyperlipidemia and hypercholesterolemia	413
Antisense approach to hypertriglyceridemia.....	413
Cholesterol reduction by genetic engineering of PCSK9 gene	413
Inactivating variants in ANGPTL4 for lowering circulating triglycerides	414
Peripheral arterial disease	414
Incidence and clinical features	414
Current management	414
Gene therapy for peripheral arterial disease	415
Angiogenesis by gene therapy	415
HIF-1 α gene therapy for peripheral arterial disease.....	415
HGF gene therapy for peripheral arterial disease.....	416
Prevention of restenosis after angioplasty	416
Antisense approaches.....	416
Gene therapy to prevent restenosis after angioplasty	417
hTIMP-1 gene therapy to prevent intimal hyperplasia	418
miRNA-based gene therapy for restenosis	418
NOS gene therapy for restenosis.....	419
Techniques of gene therapy for restenosis.....	419
Maintaining vascular patency after surgery	420
Companies involved in gene therapy of cardiovascular diseases	420
Future of gene therapy of cardiovascular disorders.....	421

8. Gene therapy of viral infections..... 423

Introduction	423
Acquired Immunodeficiency Syndrome (AIDS).....	423
Current management of AIDS.....	423
Gene therapy strategies in HIV/AIDS.....	424
Cell/gene therapies for HIV/AIDS	425
Anti-HIV ribozyme delivered in hematopoietic progenitor cells	425
Autocrine interferon (INF)- β production by somatic cell gene therapy	425
Gene editing for HIV-1.....	425
Transplantation of genetically modified T cells	426
Transplantation of genetically modified hematopoietic cells	427
Inhibition of HIV-1 replication by lentiviral vectors	428
VRX496-T	428
Insertion of protective genes into target cells	429
HIV/AIDS vaccines.....	429
Intracellular immunization.....	430
Engineered cellular proteins such as soluble CD4s.....	430
Intracellular antibodies	431
Anti-rev single chain antibody fragment.....	431
Use of genes to chemosensitize HIV-1 infected cells.....	431
Antisense approaches to AIDS	431
RNA decoys.....	431
Antisense oligodeoxynucleotides	432
RNA decoys.....	432
Ribozymes	432
RNAi applications in HIV/AIDS	433
siRNA-directed inhibition of HIV-1 infection	433
Role of the nef gene during HIV-1 infection and RNAi	434
Bispecific siRNA constructs.....	434
Targeting CXCR4 with siRNAs	434
Targeting CCR5 with siRNAs.....	434
Companies involved in developing gene therapy for HIV/AIDS	435
Conclusions regarding gene therapy of HIV/AIDS.....	436
Genetic vaccines for other viral infections	436
Cytomegalic virus infections	436
Viral hepatitis	437
Vaccine for hepatitis B	437
Vaccine for hepatitis C.....	437
Gene therapy for hepatitis C.....	438
Vaccine for herpes simplex virus.....	438
DNA vaccine against rabies	438
DNA vaccine for Ebola	439
Vaccines for avian influenza	439
Future prospects of DNA vaccines for avian influenza	440
Human trial of a DNA vaccine for avian influenza	441
Companies developing genetic vaccines for infections other than AIDS	441

9. Research, Development and Future of Gene Therapy.....	443
Basic research in gene therapy	443
R & D in gene therapy	443
Animal models of human diseases for gene therapy research	444
<i>Lentiviral transgenesis.....</i>	444
Financing research and development.....	444
Role of the NIH in gene therapy research.....	444
National Gene Vector Laboratories	444
Funding of gene therapy research in Europe.....	445
<i>Gene therapy funding in Horizon 2020 of European Commission</i>	445
Financing by the industry.....	446
Clinical trials in gene therapy	446
Clinical trials worldwide	446
<i>Clinical trials in cancer gene therapy</i>	447
<i>Trials of gene therapy for neurological disorders</i>	447
<i>Clinical trials for genetic disorders.....</i>	447
<i>Clinical trials in cardiovascular gene therapy</i>	447
<i>Clinical trials for infectious diseases.....</i>	447
<i>Gene therapy for other disorders</i>	447
Clinical trials in the US.....	448
Vectors used in gene therapy clinical trials	448
<i>Vector analytics for clinical trials using rAAV vectors.....</i>	449
Gene therapy in China.....	449
Future of gene therapy	450
How to improve gene therapy.....	450
International Gene Therapy Consortium.....	451
Future opportunities and challenges for gene therapy.....	452
Promising areas of application of gene therapy	453
<i>Neurological disorders</i>	453
<i>Gene therapy of cardiovascular disorders.....</i>	454
<i>Cancer gene therapy</i>	455
Personalized gene therapy	456
10. Regulatory, Safety, Ethical Patent Issues of Gene Therapy	457
Regulation of gene therapy in the United States.....	457
US Federal guidelines for research involving recombinant DNA molecules	457
Regulation of gene therapy in US	457
Implantation of genetically manipulated cells.....	457
<i>Modification of oocytes for use in IVF.....</i>	458
Clinical trials in gene therapy	458
Gene therapy INDs placed on hold by the FDA.....	459
FDA policy for advancing development of gene therapy	459
<i>Future for approval of gene therapy in the US</i>	461
Do-it-yourself gene therapy	463
Regulation of gene therapy in Europe.....	463
European Union	463
Regulation of gene therapy in Germany	464
<i>Preclinical research</i>	464
<i>Clinical Trials.....</i>	465
Marketing authorization	466
Regulation of gene therapy in the United Kingdom	466
Regulation of gene therapy in France.....	467
Regulation of gene therapy in Italy	467
Regulation of gene therapy in the Netherlands.....	467
Gene therapy regulation in Switzerland.....	469
Regulation of gene therapy in Australia.....	469
Regulation of gene therapy in Japan.....	470
Regulation of gene therapy in China	470
Safety issues of gene transfer	470
Adverse effects of retroviral vectors	471
<i>Insertional mutagenesis.....</i>	471
Adverse effects of HSV vectors	471
<i>Neurotoxicity of HSV vectors</i>	471
<i>Hepatotoxicity of HSV-tk/ganciclovir approach.....</i>	472
Adverse effects of adenoviral vectors.....	472
<i>Inflammatory effects of adenoviruses in lungs</i>	472
<i>Inflammatory effects involving the liver.....</i>	472
<i>Induction of immune response by adenoviral vectors.....</i>	473
<i>Impairment of adrenocortical steroidogenesis.....</i>	473
<i>Adverse effects of AAV vectors</i>	473
Toxicity associated with cationic lipid-mediated gene transfer	474

Toxicity of lipopolysaccharides	474
Potential side effects of RNAi gene therapy	474
Role of molecular diagnostics in safety of gene therapy	475
Quality control of vectors	475
<i>Testing for retroviruses</i>	475
<i>Adenoviral vectors</i>	476
<i>Replication competent viruses</i>	476
Genetic characteristics of viral vectors	476
GMP-compliant viral vectors for human gene therapy	477
Concluding remarks about safety of viral vectors	477
Ethical aspects of gene therapy	477
The lay consumer's view of somatic gene therapy ethics	478
Ethical aspects of clinical trials	478
Regulatory and ethical issues for in utero gene therapy	478
Ethical aspects of germline gene therapy	479
Ethical aspects of mitochondrial replacement therapy	479
Ethical aspects of gene editing	480
<i>Ethical aspects of clinical trials of germline editing</i>	480
<i>Gene editing in the UK</i>	481
<i>Gene editing in the US</i>	482
<i>Guidelines for gene editing by Alliance for Regenerative Medicine</i>	483
<i>UNESCO's view on gene editing in humans</i>	484
<i>Concluding remarks on the ethical aspects of genome editing</i>	485
Germline gene therapy for genetic enhancement	485
Athletic enhancement by genetic engineering	485
<i>Gene doping in sports</i>	486
<i>Gene transfer methods used for enhancing physical performance</i>	486
<i>Adverse effect of genetic engineering</i>	488
<i>Problems in detecting genetic manipulations in athletes</i>	488
<i>Ethical dilemma</i>	488
Gene therapy patents	489
CRISP/Cas9 patents	489

Tables

Table 1-1: Landmarks in development of gene therapy	23
Table 2-1: Classification of methods of gene therapy	35
Table 2-2: A comparison of various physical methods of gene transfer	37
Table 2-3: Experimental applications of gene transfer by electroporation	39
Table 2-4: An overview of characteristics of commonly used viral vectors	47
Table 2-5: Companies using viral vectors	60
Table 2-6: Companies using nonviral vectors	79
Table 2-7: Target organs for nonviral gene therapy methods.	81
Table 2-8: CRISPR vs other gene editing tools	88
Table 2-9: Companies developing CRISPR technology	100
Table 2-10: Companies developing CAR-T cell therapy	114
Table 2-11: Potential routes for administration of DNA	119
Table 2-12: Companies with gene delivery devices/ technologies	121
Table 2-13: Strategies for targeted gene therapy	122
Table 2-14: Animal experimental studies of in vivo gene delivery with polymer systems	123
Table 2-15: Approaches to controlling gene expression in gene therapy	124
Table 2-16: Companies with regulated/targeted gene therapy and special techniques	126
Table 2-17: Potential applications of human germline genome modification	128
Table 2-18: Applications of molecular diagnostics in gene therapy	141
Table 2-19: Advantages of gene therapy compared with protein therapy	144
Table 3-1: Experimental approaches to gene therapy of rheumatoid arthritis	149
Table 3-2: Gene therapy strategies for osteoarthritis	151
Table 3-3: Cell and gene therapy approaches for type 1 diabetes mellitus	158
Table 3-4: Indications for gastrointestinal gene therapy	164
Table 3-5: Hematological disorders that can be potentially treated by gene therapy	166
Table 3-6: Clinical trials of gene therapy for hemophilia A and B	168
Table 3-7: Companies involved in gene therapy of hematological disorders	179
Table 3-8: Techniques of gene transfer to the kidneys	185
Table 3-9: Gene therapy in animal experimental models of renal disease	187
Table 3-10: Applications of gene therapy in ophthalmological disorders	196
Table 3-11: Companies developing gene therapy for eye disorders	213
Table 3-12: Strategies for gene delivery to the lungs	217
Table 3-13: Companies developing gene therapy for pulmonary disorders	224
Table 4-1: Genetic disorders that are being investigated for gene therapy	237

Table 4-2: X-linked immunodeficiency disorders	239
Table 4-3: Examples of inherited metabolic disorders amenable to gene therapy	245
Table 4-4: Gene therapy approaches to Duchenne muscular dystrophy	266
Table 4-5: Companies involved in gene therapy of genetic/metabolic disorders	284
Table 5-1: Strategies for cancer gene therapy	285
Table 5-2: Cell-based gene therapy for cancer	290
Table 5-3: Companies with nucleic acids/genetically modified cell cancer vaccines	302
Table 5-4: Enzyme/prodrug combinations employed in suicide gene therapy	307
Table 5-5: Mutation compensation strategies used clinically	307
Table 5-6: Companies developing oncolytic viruses	319
Table 5-7: Strategies for gene therapy of malignant brain tumors.....	323
Table 5-8: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	329
Table 5-9: Clinical trials of gene therapy in ovarian cancer.....	331
Table 5-10: Gene therapy for malignant melanoma.....	332
Table 5-11: Clinical trials of gene therapy for prostate cancer	337
Table 5-12: Companies involved in cancer gene therapy.....	342
Table 6-1: Example of potential indications for gene therapy of neurologic disorder	345
Table 6-2: Methods of gene transfer as applied to neurologic disorders	346
Table 6-3: Gene therapy techniques applicable to Parkinson disease	353
Table 6-4: Companies developing gene therapy for Parkinson's disease.....	361
Table 6-5: Gene transfer in animal models of carotid artery restenosis.....	370
Table 6-6: Gene therapy strategies for vasospasm.....	371
Table 6-7: Neuroprotective gene therapy in animal stroke models	372
Table 6-8: Experimental gene therapy approaches for relief of pain	381
Table 6-9: Companies involved in developing gene therapy of neurological disorders	389
Table 7-1: Cardiovascular disorders that are potential indications for gene therapy.....	391
Table 7-2: Catheter-based systems for vector delivery to the cardiovascular system.....	392
Table 7-3: Companies involved in gene therapy of cardiovascular diseases	420
Table 8-1: Strategies for gene therapy of AIDS	424
Table 8-2: Companies involved in developing gene therapy for HIV/AIDS	435
Table 8-3: Companies developing genetic vaccines for infections other than AIDS	441
Table 9-1: Geographical distribution of gene therapy clinical trials	446
Table 9-2: Opportunities and challenges for gene therapy and resources needed	453
Table 9-3: Potential applications of gene therapy in disorders of the nervous system	454
Table 10-1: Genes that may be used for performance enhancement	486

Figures

Figure 1-1: Relation of gene therapy to other biotechnologies	26
Figure 1-2: Relationship of DNA, RNA and protein in the cell	30
Figure 2-1: Ex vivo and in vivo techniques of gene therapy.....	36
Figure 2-2: Structure of the Helios gene gun.....	42
Figure 2-3: Categories of rAAV-based gene therapy strategies	50
Figure 2-4: Gene editing by zinc finger nucleases	83
Figure 2-5: Genome engineering by transcription-activator-like-effector-nucleases.....	84
Figure 2-6: Mechanism of action of GeneRide technology.....	85
Figure 2-7: A scheme of CRISPR/Cas9 gene editing	86
Figure 2-8: Use of CRISPR-Cas9 for hereditary hearing loss	98
Figure 2-9: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	113
Figure 2-10: Schematic of suppression of gene expression by RNAi.....	138
Figure 3-1: Retina and routes of administration of gene therapy for retinal disorders	202
Figure 4-1: Targeted gene correction of α 1-antitrypsin deficiency by iPSCs	248
Figure 4-2: Application of CRISPR-Cas9 in a mouse model of DMD.....	272
Figure 4-3: Techniques for mitochondrial nuclear transfer.....	282
Figure 5-1: Gene therapy approaches for pancreatic cancer	339
Figure 6-1: Effect of tyrosine hydroxylase gene delivery on dopamine levels	354
Figure 6-2: Role of cell and gene therapy in stroke according to pathology and stage.....	374
Figure 9-1: Product development cycle in gene therapy.....	443
Figure 9-2: Proportions of therapeutic areas in clinical trials of gene therapy in the US.....	448
Figure 9-3: Proportions of various vectors used in gene therapy trials	448